ELSEVIER
SAUNDERS

Emerg Med Clin N Am
23 (2005) 1251–1271

EMERGENCY
MEDICINE
CLINICS OF
NORTH AMERICA

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

Abdominal pain, acute, 384–387

Accelerated junctional rhythm, in acute coronary syndromes, 1069

Acetaminophen, 434–436
for chronic pain, 324–325

Acetazolamide, hyperchloremic anion gap acidoses and, 782

Acupuncture, use in austere environment, 597

Addiction, in chronic pain, 356–357
management strategies in, 360
problems with, 357–358
screening for, 357

Addison's disease, 692

Adenosine diphosphate receptor antagonists, in acute coronary syndromes, 1036
in unstable/non-ST elevation myocardial infarction, 1035

Adolescents, abuse of steroids by, 821

Adrenal emergencies, recognition and management of, **687–702**

Adrenal gland, incidentalomas of, 699
pathophysiology of, 692–694
physiology of, 691

Adrenal hyperplasia, congenital, 879–880

Adrenal insufficiency, clinical characteristics of, 692, 693
corticosteroid therapy and, 697–699
definition of, 692
etiologies of, 692–694
evaluation in, 696–697, 916–918, 919
features suggesting, 917
management of, 918–921
pathophysiology of, 914–916
presentation in, 694–696, 914

Afterload reduction, in cardiogenic pulmonary edema, 1114–1115

AIDS, steroids in, 822

Allodynia, 309

Alma Ata declaration, 151–152

Alternative medicine, complementary, 532–533
traditional, 533

Amenorrhea, osteopenia in, 793

American Academy for Emergency Medicine in India, 8

American Academy of Emergency Medicine, 6

American Board of Medical Specialties (ABMS), 259–260

American College of Emergency Physicians (ACEP), 3, 4–5, 261

Amiodarone, as cause of hypothyroidism, 653
thyroiditis induced by, 672

Anabolic steroids, **815–826**
abuse of, by adolescents, 821
epidemiology of, 815–816
adverse effects of, 819–820
effects on organs, 816
efficacy of use of, 818
physiology of, 816
trade names of, 819
use in medical practice, 821–823

Androstenedione, 803–804

Anesthesia, compression, use in austere environment, 597
local and topical, in prehospital pain management, 424
regional, advantages of, 487
ankle blocks, 493–494
contraindications to, 487
disadvantages of, 487–488
facial and oral blocks, 496–499
for hand, 490–491
general techniques of, 488
indications for, 487

0733-8627/05/$ - see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/S0733-8627(05)00097-0

Anesthesia, compression (*continued*)
intercostal block, 495–496
intravenous, 491–493
use in austere environment, 592–596
wrist blocks, 488–489

Anesthetics, local, addition of vasoconstrictors to, 486–487
allergic reactions to, 480–481
and peripheral nerve blocks, in emergency department, **477–502**
cardiac toxicity of, 480
central nervous system toxicity of, 479–480
for subcutaneous infiltration, 484–486
injection of, reduction of pain of, 486
structure of, 477–478
toxicity of, 478–481
topical, for intact skin, 482–483
for mucosal membranes, 481
for nonintact skin, 483–484
in corneal abrasions, 383

Angina, unstable. See also *Myocardial infarction.*
unstable/non-ST elevation myocardial infarction, evaluation course for, 1058
treatment of, **1027–1042**
based on risk assessment, 1029
benefit of, 1027–1028
recommendations for, 1028–1039

Angiotensin-converting enzyme inhibitors, in unstable/non-ST elevation myocardial infarction, 1033

Anion gap acidoses, elevated, ethylene glycol poisoning and, 779–780
etiologies of, 772–781
in lactic acidosis, 777–779
in salicylate toxicity, 780–781
iron and, 776–777
isoniazid and, 776
ketoacidoses and, 774–775
methanol and, 773
paraldehyde and, 775
uremia and, 773–774
hyperchloremic, acetazolamide and, 782
etiologies of, 782–784
hyperalimentation and, 781–782
in diarrhea and diuretics use, 783–784
in pancreatic fistula, 784
in ureteroenterostomy, 784
renal tubular acidoses and renal insufficiency and, 782–783

Ankle blocks, use in austere environment, 594–595

Anorexia nervosa, 792–794

Anticonvulsants, as cause of hypothyroidism, 653–654

Antidiuretic hormone, inappropriate secretion of. See *SIADH.*

Anti-emetic medications, in migraine headaches, 372–373

Antinociceptive response system, 310
endogenous opioids in, 310

Anxiety, in endocrine and metabolic disorders, 906–907

Aortic aneurysm, abdominal, 1170–1173
management of, 1173–1174

Aortic catastrophes, challenges, controversies, and advances in, **1159–1177**

Aortic dissection, 944–948
acute, 1162–1163
blood pressure on presentation in, 1166
clinical presentation of, 945
diagnostic evaluation in, 945–946
diastolic murmur in, 1166
ECG abnormalities in, 1168–1169
epidemiology of, 944–945
imaging in, 946
in severe hypertension, 1151
in young patient, 1163–1164
isolated, 1169
neurologic deficits in, 1165
percutaneous management of, 1169–1170
risk management strategies in, 947–948
serum markers in, 1167–1168
syncope in, 1164–1165
treatment of, 946–947

Aortic ulcer, peentrating, and intramural hematoma, 1159–1160
penetrating, natural history of, 1160–1162

Arrhythmia(s), as complication of acute coronary syndromes, **1065–1082**
in acute myocardial infarction, 1066
in children, 1242

Asian Society for Emergency Medicine, 7

Aspirin, in unstable/non-ST elevation myocardial infarction, 1028–1030

Asystole, in acute coronary syndromes, 1074

Atherosclerosis, 965

Atrial contractions, premature, in acute coronary syndromes, 1067

Atrial fibrillation, anticoagulation in, 1135, 1136
cardioversion in, 1134–1135
causes of, 1128
disposition in, 1135–1136
electrocardiogram in, 1129
history taking in, 1128–1129
in acute coronary syndromes, 1068–1069
in hemodynamically unstable patient, management of, 1130–1131
temporal considerations in, 1131–1132
laboratory evaluation in, 1130
management of, 1130
in emergency department, **1127–1139**
pathophysiology of, 1127–1128
physical examination in, 1129
rate control in, 1132
rhythm control in, 1133–1134

Atrial flutter, in acute coronary syndromes, 1068

Atrioventricular blocks, in acute coronary syndromes, 1070–1074

Audio, synchronous, visuals, and chat, for emergency medicine, 223

Axillary blocks, use in austere environment, 595

Ayurveda, 537–538

B

Barbiturates, for pediatric sedation, 405

Bariatric surgery, nutritional consequences of, 796–797

Behavioral techniques, in pain management, 401, 425

Benzodiazepines, for pediatric sedation, 404
in prehospital pain management, 423

Beta-blockers, actions of, 1199–1200
in unstable/non-ST elevation myocardial infarction, 1030–1031
toxicity of, 1200–1202

Beta-hydroxy-beta-methylbutyrate, 802–803

Bicarbonate, in diabetic ketoacidosis, 620–621, 622
in hyperkalemia, 743

Bier block, 491–493

Biliary colic, 375–376

Bioelectromagnetics, 542–543

Biomarkers, cardiac. See *Cardiac biomarkers.*

Blood draws, techniques for, in children, 406

Blood pressure, on presentation, in aortic dissection, 1166

Bone, anatomy of, 703–704
and mineral metabolism, **703–721**
effects of steroids on, 817–818
metabolism of, abnormalities of, management in, 706–707
pathophysiology of, 705–706
presentation in, 705
normal, 704–705

Boston University RESPECT model for cultural competency, 165

Botanical medicine, pain and, 541–542

Brachial plexus blocks, use in austere environment, 595

Bradyarrhythmias, in acute coronary syndromes, 1069–1070

Brain, interpretation of pain sensations by, 281

Brief Pain Inventory, 290–293

Bulimia nervosa, 794–795

Bundle branch block, left, in acute coronary syndromes, 1000–1010

Bupivacaine (Marcaine), 485

Burns, severe, steroids in, 822–823

Butorphanol, intranasal, 590

C

Cachexia, 791

Calcium, metabolism of, 707–708

Calcium channel blockers, classes of, 1197
in unstable/non-ST elevation myocardial infarction, 1033
toxicity of, 1197–1198

Cannabinoids, in pain management, 471–472

Cardiac biomarkers, advances in, **959–975**
assays of, 960
elevations of, in cardiac contusion, 971
in myocarditis or myopericarditis, 971
in pulmonary embolism, 970
in sepsis and critical ilness, 971
in acute coronary syndromes, 977–978
point-of-care testing with, 960–961
technical aspects of, 959–961
testing guidelines for, 961

Cardiac care, emergency, access problems/delay interval and, 1219–1221
emergency medical service aspects of, **1219–1231**
emergency medical services system response in, 1222–1224
emergency medical services use in, 1221–1222
interfacility transports for, 1228–1229
prehospital ECG and, 1224–1225
prehospital thrombolysis and, 1225–1228
public access defibrillation and, 1228

Cardiac contusion, elevations of cardiac biomarkers in, 971

Cardiac glycosides, 1206–1210

Cardiac ischemia, biomarkers of, in myocardial infarction, 965–967

Cardiovascular challenges in toxicology, **1195–1217**

Cardiovascular diseases, international emergency medicine and, 241

Cardiovascular emergencies, in pediatric patient, **1223–1249**

Cardioversion, in atrial fibrillation, 1134–1135

Catecholamine administration, exogenous, effects on endocrine system, 924

Causalgia, 308

Celecoxib, 450

Center for International Emergency Medicine System, 7

Centers for Disease Control and Prevention, 96

Central nervous pressure, ultrasound to estimate, 1191

Cerebral edema, in diabetic ketoacidosis, 623–624
in hyperosmolar hyperglycemia state, 644–645

Chest pain, as diagnostic challenge, 937
cocaine-associated. See *Cocaine-associated chest pain.*
initial evaluation of, **937–957**

Child(ren), and newborn, metabolic crisis in, emergency department approach to, **843–883**
anomalous coronary artery in, 1245
arrhythmias or congestive heart failure in, 1242
cardiovascular emergencies in, **1233–1249**
congenital heart disease in. See *Congenital heart disease, in children.*
diabetic ketoacidosis in, management of, 621
ECG in, normal changes in, 1242–1243
heart transplantation in, complications following, 1239–1241
hypertrophic cardiomyopathy in, 1247
infective endocarditis in, 1241–1242, 1243
Kawasaki Disease in, 1245–1246
myocarditis in, 1246–1247
pain in. See *Pediatric pain.*
sedation of, 394, 403–406
supraventricular tachycardia in, 1244
Wolff-Parkinson-White syndrome in, 1244–1245

Child abuse, international emergency medicine and, 66

Chinese herbs, for pain treatment, 537

Chinese medicine, 536–537

Chiropractic, 539

Chronic pain syndromes, 328–330

Circulation, assisted, in cardiogenic pulmonary edema, 1118

Cocaine, pharmacology of, 1084–1086

Cocaine-associated chest pain, **1083–1103**
differential diagnosis of, 1088–1089
dysrhythmias in, 1095
evaluation of, 1089–1093
history and epidemiology of, 1083–1084
pathophysiology of, 1086–1088

stress testing in, 1092
treatment of, 1093–1095

Codeine, 313–314, 457–458

Cognitive-behavioral techniques, in chronic pain, 323

Cognitive therapies, in pain management, 400, 425

Coma, in metabolic disorders, 904

Complex regional pain syndrome, 309, 328–329

Computerized tomography, and angiography, in acute coronary syndromes, 983–986

Conduction disturbances, in acute coronary syndromes, 1066

Conflict, modern, and humanitarian environment, 116–120
change in conduct of war in, 118
civilians as targets in, 116–117
"CNN factor" and role of media, 119–120
ethnic regional violent, increase in, 116
increased humanitarian aid worker morbidity and mortality in, 119
increased military involvement in conflict settings, 119
modern combatants in, 117
proliferation of nongovernment organizations in, 118–119
urbanization and larger populations at risk in, 117

Congenital heart disease, in children, corrected, evaluation of, 1237–1239
Fontan procedure in, 1238, 1239
sudden death and, 1238
suspected, evaluation in, 1233–1237

Congestive heart failure, in children, 1242

Coproporphyria, hereditary, 896

Corneal abrasions, 382–384
cycloplegics in, 382–383
eye patching in, 382
nonsteroidal anti-inflammatory drugs in, 383
oral opiates in, 383
topical anesthetics in, 383

Coronary artery, anomalous, in children, 1245
occlusion of, myocardial necrosis after, 1044

Coronary intervention, percutaneous, in unstable/non-ST elevation myocardial infarction, 1038–1039

Coronary syndromes, acute, 938–944
arrhythmic complications of, **1065–1082**
cardiac markers for, 941
chest pain observation units and stress testing in, 941–942
clinical presentation of, 939
diagnostic evaluation of, 939
ECG diagnosis of, ECG patterns confounding, **999–1025**
epidemiology and risk of, 938–939
medical decision-making and clinical strategies in, 1021–1024
risk management strategies in, 942–944
suspected, noninvasive imaging techniques in, **977–998**

Corticosteroid insufficiency. See *Adrenal insufficiency*.

Corticosteroid therapy, adrenal insufficiency and, 697–699

Cortisol, stress-induced release of, in critical illness, 912–913

Creatine monohydrate, 800–802

Cryoanalgesia, use in austere environment, 597

Cultural practices in folk medicine, 544

Cyclooxygenase-2 agents, controversies concerning, 450–451
description of, 441–442
efficacy of, 443–444
interactions with other drugs, 444–445
pharmacology of, 442
precautions in use of, 445
safety and adverse effects of, 445–446
safety megatrials, 446–448
selectivity of, 442–443
specific, 449

Cyclooxygenase-2 inhibitors, and vascular events, 448–449
for chronic pain, 325

Cycloplegics, in corneal abrasions, 382–383

D

Data collection, in international emergency medicine, 235–237

Deafferentiation, producing pain, 309

Defibrillation, public access, emergency cardiac care and, 1228

Delta-aminolevulinate dehydratase deficiency porphyria, 897–898

Dementia, delirium, and disorientation, in endocrine and metabolic disorders, 905

Depression, clinical, in endocrine and metabolic disorders, 906

deQuervain's thyroiditis, 671

DHEA, 804–805

Diabetes insipidus, 827–832
differential diagnosis of, 828–829
evaluation in, 829–830
pathophysiology of, 828–829
presentation in, 828
treatment of, 830–831

Diabetic ketoacidosis, **609–628**, 774–775
bicarbonate in, 620–621, 622
complications of, 622–625
differential diagnosis of, 613
disposition in, 625
elevated anion gap acidosis in, 774–775
history and epidemiology of, 609–610
hyerglycemia in, 611, 614
in pediatric patients, management of, 621
insulin in, 618–619, 621–622
intravenous fluid therapy in, 617–618, 621
ketogenesis in, 611
laboratory evaluation in, 615–616
management of, 616–621
pathophysiology of, 610–612
phosphate in, 621
physical examination in, 613–615
potassium in, 619–620
precipitating factors in, 610
presentation in, 610

Diaster relief, degree or certificate courses in, 127

Dietary supplements, 799–806
botanical, in pain syndromes, 540

Digital blocks, use in austere environment, 596

Disease(s), and effects of medications and procedural interventions, 231
mortality and burden of, causes of, 14, 15

Domestic violence, international emergency medicine and, 66

Doppler ultrasound, 1182–1183

Drug abuse, 351–355
problems caused by, 353–354
screening for, 352–353

Drug Enforcement Administration, actions of, 579

Drug-seeking behavior, 524–525

Drug-seeking patient(s), in emergency room, **349–365**
management of, in acute care setting, 359–361

Drugs. See *Medications*.

Dynorphin, 311

E

Eating disorders, 791–796
medication abuse in, 795–796

Echocardiography, 1180
and ultrasound, in emergency department, **1179–1194**
transthoracic, in acute coronary syndromes, 978–979

Educational Commission for Foreign Medical Graduates (ECFMG), 201

Elderly, hyperthyroidism in, 676

Electrocardiography, abnormalities on, in aortic dissection, 1168–1169
in acute coronary syndromes, 940–941, **999–1025**
in atrial fibrillation, 1129
normal changes in, in children, 1242–1243
prehospital, emergency cardiac care and, 1224–1225
to assess undifferentiated hypotension, 1192
to guide cardiac pacing, 1192

Electrolyte disturbances, 866

Electromagnetic therapy, 542–543

Emergency Board of Emergency Medicine (ABEM), 262

Emergency care, development of, in U.S., 260–261

Emergency department, pain assessment instruments for use in, **285–295**
pediatric, pain-free, creation of, 408–410
special populations in, 525

Emergency International, 7

Emergency medical care, global, becoming specialty in, and impact of, **259–269**

Emergency medical services, system response in, in emergency cardiac care, 1221–1222
use in emergency cardiac care, 1221–1222

Emergency Medical Services (EMS), 261

Emergency medical systems, in U.S., 105–107
dimensional analysis of, 105–106
focus of, 109–111
training in, 107–109
universal, challenge(s) of, financing as, 111
quality assurance as, 111–112
research as, 112

Emergency Medical Treatment and Labor Act (EMTALA), 263–264

Emergency medicine, around world, history of, **1–10**
as specialty, role in U.S. in promoting, 266–268
basic pharmacology and advances in, **433–465**
cardiac. See *Cardiac care, emergency.*
definitions of, 136–137
development of, as specialty in U.S., 260–261, 265–266
countries with, 33–34
funding for, 244–245
Grand Challenges versus Global Burden of Disease, 245, 246
in Africa, 41–42
in Asia/Western Pacific Region, 40–41
in Costa Rica, 37–38
in Europe, 32–35
in Latin America, 36–37
in Mexico, 38
in Middle East, 39–40
in North America, 35–36
in South America, 38–39
observational exchange program in, 206
prehospital care and, 243
public education and, 243–244
trauma response and, 242–243
funding of development of, funding agencies and, 49
funding process for, 52–54, 55
in low- and middle-income countries, **45–56**
lending agencies in, 47–48
multilateral investment banks and, 50–51
United Nations system and, 50
global. See *Emergency medicine, international.*
global interest in, 218
in United States, as not suitable for all countries, 138–139
international, access to, healthy inequity and, 60
activities in, 1–2, 202–203
burden of disease and, 58
capacity building in, 233–234
cardiovascular disease and, 67–69, 241
child abuse and, 66
collaboration in, 20
continuing medical education and, 71–72
delivery systems for, compared, 136–139
development of, advocacy for, 19–20
determination of level of, 25
education and training in, 142–144
general approach to, 134–136
guiding principles of, 16–18
in resource-constrained settings, 25–26
in urban settings, 27
international organization's involvement in, 3–8
lessons learned from, **133–147**
needs assessment and strategic planning in, 22
priorities in, **11–29**
regional highlights in, **31–44**
research in, 24
specialty model for, 139–142
disaster preparedness and, 70–71
domestic violence and, 65
education and training in, 22–23
educational planning for, 182–184
environmental evaluation in, 184
equity in emergency care and, 20–22
ethics and institutional review in, 245–249
fellowship training, goals of, 202–203, 204
health care improvement domains in, 234
health care systems issues and, 70
health-related quality of life and, 238

Emergency medicine (*continued*)
hospital accreditation and, 72–74
hot topics in, **57–83**
human resources in, 74–75
injury triangle and, 59
intentional injuries and, 65, 239–240
locus of research in, defining of, 234–235
design and data collection in, 235–237
research in, current state of, 237–241
medical capabilities of countries and, 138–139
mental health and, 69–70, 241
noninfectious disease and, 67, 240
nonoccupational unintentional injuries and, 64
occupational injuries and, 63–64
outcomes research in, 237
political considerations in, 185
programs for, analysis of, 184–187
assessment of, 186–187, 188, 189
development of, 180–182
and implementation of, **177–197**
evaluation of, 191–193
implementation of, 191
needs assessment for, 185–186
planning of, 187–191
troubleshooting for, 192
types of, 178
public education in, 24–25
readings and references in, 75–78
regional development of, factors influencing, 185
research agendas in, **231–257**
research fundamentals in, 233–237
research in, documents outlining ethics of, 248
respiratory illness and, 69, 241
road crashes and, 61–63
role of emergency medicine physicians and, 58–59
self-inflicted injuries and, 66–67, 240
short courses and training opportunities in, 204
specialty development in, 23–24
specialty model versus multidisciplinary model, 179
systems of, compared, 179–180
development of, 70
training programs for, 181–182, 183
understanding systems of, 178–180
unintentional injuries and, 60, 238–239
war and, 67, 68
worldwide systems of, 179
international fellowships in, **199–215**
mediated learning programs in, 227
role in organized system of care, 264–265
specialty status for, 261–262
status of, in different countries, 8–9
systems of, early, development of, 2–3
telecommunication technologies for, 225–227
training and education in, appropriate technologies for, 219–220
asynchronous instructional delivery for, 224
compressed video for, 222–223
distance-based technologies for, **217–229**
expert site visits for, 218
funding sources for, 219
hybrid instructional design of, 224–225
live video for, 221
mediated learning in, 220–221
synchronous audio, visuals, and chat for, 223
synchronous instructional delivery for, 221
"teach the teacher" aspects of, 219
uncompressed (point to point) video for, 221–222

Emergency medicine services, background of, 199–202
residency training in, 201

Emergency medicine training programs, observational, activities for non-U.S. physicians participating in, 207
opportunities in, for non-U.S. medical graduates, 208–209, 211
positions in, as competitive, 210–211
structural observational, 206

Emergency physician(s), definitions of, 136–137
generalist, value of, 263
in international humanitarian assistance, **115–131**
primary skill of, 263
role of, in international emergency medicine, 58–59

roles in humantarian assistance, 124–129
specialty status and characteristics of, significance of, 262–263
supporting open access to care, 263–264

Encephalopathy, hypertensive, in severe hypertension, 1148

Endocarditis, infective, in children, 1241–1242, 1243

Endocrine response, to critical illness, hypothalamus-pituitary-adrenal axis and, 912–913
somatotropic axis and, 910–911
thyrotropic axis and, 911–912
update on, **909–929**

Endocrine system, disorders of, altered mental status due to, **901–908**
effects of exogenous catecholamine administration on, 924

Endogenous opioids, 282

Endorphins, 310–311

Enkephalins, 311

Enzyme deficiencies, heme synthesis pathway with, 886, 887

Ephedra, 805

Ergot alkaloids, in migraine headaches, 373–374

Erythropoietic porphyria, congenital, 896–897

Erythropoietic protoporphyria, 894

Ethics, in international emergency medicine, 245–249

Etomidate, for pediatric sedation, 405
for procedural sedation and analgesia, 511–513

European Society for Emergency Medicine, 6–7

F

Faces pain scale, 290, 420

Fad diets, 797

Fatigue, due to metabolic disorders, 901–902
in electrolyte disturbances, 902
in thyroid dysfunction, 902

Federal and state barriers to pain management, 575–578
initiatives to reduce, 576–579

Federation of State Medical Boards, model guidelines from, 578–579

Fellowships, international, in emergency medicine, **199–215**

Femoral blocks, use in austere environment, 593–594

Fentanyl, 460, 505
adverse events associated with, 560–561
in prehospital pain management, 422

Fentanyl citrate, 589–590

Fibrinolysis, in acute myocardial infarction, 1048–1051, 1053, 1056

Fibromyalgia, 329

Fluid therapy, in sickle cell disease, 379

Fuel metabolism, disorders of, **789–813**
associated with abnormal fuel expenditure, 798–806
associated with abnormal intake, 790–796
management in, 797–798

Furosemide, in cardiogenic pulmonary edema, 1112

G

Gastric dilation, acute, in diabetic ketoacidosis, 624–625

Gastrointestinal tract, decontamination of, in cardiovascular toxicity, 1197

Gate control theory, 282

Gene therapy, in pain management, 472

Global Burden of Disease report, 232

Global health, definition of, 150
experience in, development of, 153–173

Glucose control, during critical illness, 922, 923

Glucose homeostasis, management in, 921–922
pathophysiology of, 921
presentation in, 921

Glycoprotein IIb/IIa receptor antagonists, in unstable/non-ST elevation myocardial infarction, 1036–1037

Governmental organizations, for funding of relief and development, 122–123

Graves' disease, 670–671, 676

Growth hormone, in critical illness, 910–911

H

Haddon matrix, prevention of injuries and, 87–88

Hashimoto's thyroiditis, 652, 671

Headaches, chronic, 330

Health, international. See *International health.*

Health care, improvement domains of, in international emergency medicine, 234

Heart, anatomy of, 1180, 1181
physiology of, 1196
ultrasound of. See *Ultrasound, of heart.*

Heart block, complete, in acute coronary syndromes, 1072–1073

Heart failure, brain natiuretic peptide and, 967–970
congestive, 967–970
troponins and, 970

Heart transplantation, in children, complications following, 1239–1241

Hematoma, intramural, natural history of, 1160–1162
pathophysiology of, 1160
penetrating aortic ulcer and, 1159–1160

Hematopoiesis, steroids and, 818

Heparin, in acute coronary syndromes, 1035
in unstable/non-ST elevation myocardial infarction, 1034

Homeopathy, 538–539

Hormones, changes in, during critical illness, 915

Humanitarian assistance, defined, 120–124
degree or certificate courses in, 127
emergency physicians in, knowledge/areas of special expertise of, 126
limitations of, 124–125
preparation of, 126–128
roles of, 124–129
suitability of, 124, 125
future needs in, and roles for emergency medicine, 128–129
gaining experience in, 128
international, emergency physicians in, **115–131**
main actors in, 121–122
militaries in, 123–124
private industry, consulting firms, and academic organizations in, 123
provision of, top priorities for, 121

Humanitarian environment, modern conflict and, 116–120

Hydrocodone, 458

Hydromorphone (Dilaudid), 458–459

Hyperalgesia, 308

Hyperbilirubinemia, conjugated, differential diagnosis of, 865
evaluation in, 864–865
management and disposition in, 865
unconjugated, differential diagnosis of, 862–863
evaluation in, 863
management and disposition in, 863, 864

Hypercalcemia, in infant, differential diagnosis of, 873–874
evaluation in, 874
management and disposition in, 874
presentation in, 873
management of, 711–712
pathophysiology of, 709–711
presentation in, 708

Hyperchloremia, in diabetic ketoacidosis, 623

Hyperglycemia, in diabetic ketoacidosis, 611, 614, 623

Hyperkalemia, case illustrating, 733–734
clinical manifestations of, 735
etiologies of, 735–740
in newborn, differential diagnosis of, 877
evaluation in, 877
management and disposition in, 877–878
presentation in, 876–877
management of, 740–744

Hypermagnesemia, in newborn, 878–879

Hypernatremia, 749, 750–752
classification of, 762–763
definition of, 759–761
evaluation in, 763–764
in neonate, differential diagnosis of, 869
evaluation in, 869
management and disposition in, 869–870

presentation in, 868
incidence of, 761
management of, 764–765
presentation in, 761

Hyperosmolar hyperglycemic state, **629–648**
cerebral edema in, 644–645
complications of, 644–645
dehydration in, 644
diagnostic features of, 629
differential diagnosis of, 636
disposition in, 645
epidemiology of, 630–631
evaluation in, 636–639
insulin in, 643–644
laboratory values in, 636–637, 638–639
management in, 639–644
measured sodium in, 638
osmolality in, 637
pathophysiology of, 634–636
potassium depletion in, 638
potassium in, 642–643
precipitating factors in, 631–632, 633
presentation of, 630–634
rhabdomyolysis in, 645

Hyperphosphatemia, 714

Hypertension, severe, acute ischemic stroke in, 1150–1151
acute left ventricular failure in, 1152
aortic dissection in, 1151
autoregulation in, 1145
clinical evaluation in, 1144
hypertensive encephalopathy of, 1148
hypertensive urgencies in, 1152–1153
in emergency department patient, **1141–1158**
causes of, 1142
intracerebral hemorrhage in, 1149
management of, 1145–1152
goals of, 1145–1146
myocardial ischemia or infarction in, 1151
pathogenesis of, 1142–1144
pharmacologic management of, 1146–1148
renal insufficiency in, 1152
subarachnoid hemorrhage in, 1149–1150
uncontrolled, 1154

Hyperthyroidism, **669–685**
clinical features of, 672
disposition in, 682
epidemiology and pathology of, 669–670
etiologies of, 670–672
in elderly, 676
laboratory diagnosis in, 678–679
physical examination in, 674–676
symptoms of, 672–674
treatment of, 679–682

Hypertrophic cardiomyopathy, in children, 1247

Hypoaldosteronism, hyperkalemia in, 737–738

Hypocalcemia, disposition in, 713
evaluation of, 710
in newborn, differential diagnosis of, 870–871
evaluation in, 871
management and disposition in, 871–872
presentation in, 870
management in, 712–713
pathophysiology of, 712
presentation in, 712

Hypoglycemia, in diabetic ketoacidosis, 622
in neonates, born in emergency department, 846–847
definition of, 843–844
differential diagnosis of, 845–846
disposition in, 848
evaluation in, 847
long-term outcome of, 848–849
management of, 847–848
physiology of, 844
presentation in, 844–845

Hypokalemia, clinical signs of, 726–727
definition of, 725
electrocardiographic changes in, 727
etiologies of, 728–731
in diabetic ketoacidosis, 622
in infant, differential diagnosis of, 875
evaluation in, 875–876
management and disposition in, 876
presentation in, 875
organ system effects of, 726
treatment of, 731–733

Hypomagnesemia, in infant, 872
neurologic abnormalities in, 905

Hyponatremia, 749, 750–752
classification of, 752–756
definition of, 752
evaluation in, 757
in neonate, 866–868
differential diagnosis of, 867–868
evaluation in, 868

Hyponatremia (*continued*)
management and disposition in, 868
presentation in, 867
presentation in, 752
treatment of, 757–758
complications of, 758–759

Hypophosphatemia, 714–716

Hypotension, undifferentiated, electrocardiography to assess, 1192

Hypothalamus-pituitary-adrenal axis, in critical illness, 914

Hypothyroidism, **649–667**
clinical features of, 654–657
etiology of, 651–654
iodine-induced, 653
laboratory evaluation in, 657–659
management of, 659
medications causing, 652–654
pathophysiology of, 650–651
physical examination in, 656–657
presentation in, 654
primary, causes of, 651–652
signs and symptoms of, 655
spontaneously occurring, 649–650
symptoms of, 649

I

Idioventricular rhythm, accelerated, in acute coronary syndromes, 1075

Illness(es), critical, endocrine response to, update on, **909–929**
hormonal changes during, 915

Inborn errors of metabolism, 849, 850–851
differential diagnosis of, 853
evaluation in, 853–858
management of, 858–859
mortality associated with, 860–861
outlook in, 861
presentation in, 849–853
treatment of, 859

Incidentalomas, of adrenal gland, 699

Infection(s), risk of exposure to, in international travel, 170–171

Injury(ies), and "injury pyramid", concept of, 86–87
causes of, "options analysis" and, 88
classification of, 86
control of, education to promote safe behavior, 91
enforcement of safe behavior and, 91–92
engineering for, 92–93
three "Es" of, 90–93
epidemiology of, general concepts of, 85–87
fatalities from, causes of, 86–87
global burden of, 85–86
global public health response to, 93–96
international emergency medicine and, 59, 60, 63–64, 65, 66–67
interventions in, active versus passive, 90
prevention of, and international public health initiatives, **85–98**
emergency medicine and, 93
general concepts of, 87–93
Haddon matrix and, 87–88
"public health approach" to, 88–90

Inotropic support, in cardiogenic pulmonary edema, 1114–1115, 1115–1117

Instruments, pain assessment. See *Pain assessment instruments.*

Insulin, in diabetic ketoacidosis, 618–619, 621–622

Integrated Management of Childhood Illness, of UNICEF, 16

International emergency medicine. See *Emergency medicine, international.*

International Federation for Emergency Medicine, 3

International fellowships, in emergency medicine, **199–215**

International health, academic preparation for, 161–162
advisor/mentor for, identification of, 160–161
at home, 172–173
background of, 150–153
career development in, 157–159
cultural orientation for, 163–165
developing experience in, 153–173
career description in, 157–160
timing and duration of, 155–157
type of, 155
evaluation of, post World War II stages of, 150, 151
family issues in, 160
funding for, 160
health care issues associated with, 168–171
language training for, 162–163, 164
logistical details of participation in, 171
major actors in, 46–48
motivations for service in, 154

multinational and intergovernmental organizations in, 156–157
personal attributes in, 160
personal safety for work in, 166–168
priorities in, 13–16
programs and organizations in, 158–159
resources in, 173–174
reverse culture shock and, 171–172
traveler's medical kit for, 169

International humanitarian assistance, emergency physicians in, **115–131**

International Medical Corps, 7

International medical graduates (IMG fellowships), fellowship training for, 204–211, 212–213

International organizations, 122

Intramuscular injections, techniques for, in children, 407

Intravenous lines, techniques for, in children, 406

Intraventricular block, in acute coronary syndromes, 1073–1074

Investment banks, multilateral, funding of emergency medicine and, 50–51

Iron, elevated anion gap acidosis and, 776–777

Isoniazid, elevated anion gap acidosis and, 776

J

Jaundice, in newborn, 861–865

Joint Commission on Accreditation of Health Care Organizations, liability concerns and, 580–582

Junctional bradycardia, in acute coronary syndromes, 1070

K

Kawasaki Disease, in children, 1245–1246

Ketamine, 506–507
adverse events associated with, 561–562
for pediatric sedation, 404
use in austere environment, 591–592

Ketoacidoses. See *Diabetic ketoacidosis.*

Ketorolac, in sickle cell disease, 381

L

Lactic acidosis, elevated anion gap acidosis in, 777–779

Learning programs, mediated, in emergency medicine, 227

Legal issues, in pain management, **573–584**

Lethargy, in metabolic abnormalities, 903–904

Levobupivacaine, 485

Lidocaine (Xylocaine), 484–485

Loop diuretics, in cardiogenic pulmonary edema, 1112

Low back pain, 329–330
acute, 367–372
adjuvant therapy in, 370–371
drug therapy in, 369
expectation management in, 368–369
muscle relaxants in, 370
natural history of, 368
nonsteroidal anti-inflammatory drugs in, 369–370

Lumbar puncture, techniques for, in children, 407

M

Magnesium, metabolism of, 716–719

Magnetic resonance angiography, in acute coroanry syndromes, 989

Magnetic resonance imaging, in acute coronary syndromes, 986–988

Magnetic therapy, 542–543

Malaria, as health risk for international travelers, 170

Malnutrition, 790–791

Massage, in pain therapy, 534–535

Mayday Project, 576–578, 580

Medical graduates, U.S., fellowship training for (USMG fellowships), 202–204
international emergency medicine fellowship programs for, 204–211

Medical service, international, preparing for, **149–175**

Medications, and procedural interventions, effects on diseases, 231
causing cardiovascular toxicity, epidemiology of, 1195
management of, 1196–1197

Medicines Sans Frontieres, 7

Mental health, international emergency medicine and, 241

Mental status, altered, due to metabolic or endocrine disorders, **901–908**

Meperidine (Demerol), 354–355, 456–457

Mepivacaine, 485–486

Metabolic acidosis, definition of, 771–772
differential diagnosis of, **771–787**
etiologies of, 772
types of. See *Anion gap acidoses, elevated; Anion gap acidoses, hyperchloremic.*

Metabolic crisis, newborn and childhood, emergency department approach to, **843–883**

Metabolic disorders, altered mental status due to, **901–908**
external causes of, **827–841**

Methanol, elevated anion gap acidosis and, 773

Methohexital, 506

Methylxanthines, 805–806, 1210–1211
toxicity of, 1211–1212

Midazolam (Versed), 504–505
adverse events associated with, 561

Migraine headaches, 372–375
anti-emetic medications in, 372–373
ergot alkaloids in, 373–374
nonsteroidal anti-inflammatory drugs in, 373
opiates in, 374–375
triptans in, 374

Minerals, metabolism of, 707–708

Mobitz atrioventricular blocks, in acute coronary syndromes, 1071–1072

Mood disorders, 344

Morphine, 453–455, 588
in unstable/non-ST elevation myocardial infarction, 1032

Morphine sulfate, in cardiogenic pulmonary edema, 1111–1112
in prehospital pain management, 421–422

Muscle relaxants, in acute low back pain, 370–371

Muscle tissue, effects of steroids on, 816–817

Myocardial infarction, acute, acute reperfusion therapy in, **1043–1063**
advanced prehospital protocols in, 1053–1054
biomarkers of necrosis in, 961
cardiac arrhythmias in, 1066
diagnosis of, 999
fibrinolysis in, 1048–1051, 1056
failed, percutaneous coronary intervention after, 1053
reperfusion after, clinical assessment of, 1051
incidence of, 1219
percutaneous coronary intervention in, 1051–1053, 1054–1055
reperfusion strategy in, selection of, 1055
symptom onset to treatment, impact of time from, 1046–1048
transfer protocols in, 1057–1059
biomarkers of cardiac ischemia and, 964–965
biomarkers of inflammation associated with cardiac ischemia and, 965–967
cardiac troponins and, 963–964
creatine kinase-MB isoform and, 963
in severe hypertension, 1151
ischemia-modified albumin and, 965
myoglobin and, 962–963

Myocardial ischemia, cocaine-induced, pathophysiology of, 1086–1088
severe, findings after, 1043, 1044

Myocardial necrosis, after coronary arttery occlusion, 1044

Myocardial perfusion imaging, in acute coronary syndromes, 979–983

Myocarditis, elevations of cardiac biomarkers in, 971
in children, 1246–1247

Myofascial pain syndrome, 329

Myxedema coma, in hypothyroidism, 659–665
clinical findings in, 660–661
differential diagnosis of, 661
disposition in, 665
laboratory testing in, 661–663
mangement of, 663
prognostic factors in, 665

N

N-methyl-D-aspartate receptor activation, central sensitization and, 309–310

Nalbuphine, in prehospital pain management, 422

National Institutes of Health, Fogarty International Center of, 232, 234

Nerve blocks, peripheral, and local anesthetics, in emergency department, **477–502**

Nerve fibers, peripheral, pain receptors and, 277–279

Nervous system, central, toxicity of local anesthetics, 479–480
modulation and antinociception response by, 281–282

Nesiritide, in cardiogenic pulmonary edema, 1112–1114

Newborn, and children, metabolic crisis in, emergency department approach to, **843–883**
thyrotoxicosis in, 677

Nitrates, in unstable/non-ST elevation myocardial infarction, 1031–1032

Nitroglycerin, in cardiogenic pulmonary edema, 1110–1111

Nitrous oxide, 507
for pediatric sedation, 405–406
in prehospital pain management, 423

Nonanalgesic drugs, for chronic pain, 325

Nongovernmental organizations, 118
for funding of relief and development, 122, 123

Noninfectious diseases, international emergency medicine and, 240

Nonsteroidal anti-inflammatory drugs, 436–441
adverse effects of, 439–440
formulations of, doses of, 437, 438
in acute low back pain, 369–370
in corneal abrasions, 383
in migraine headaches, 373
in prehospital pain management, 422
interactions with other drugs, 440–441
pharmacology of, 436–437
use in austere environment, 586–588

Nutritional supplements, in pain syndromes, 540

O

Obesity, 789

"Oligoanalgesia", in emergency department, 298

Operational setting, pain management in, **585–601**

Opioids, addiction to, 355–358
adverse events associated with, 558, 559–560
as barriers to pain treatment, 301–302
compassionate refusal of, 360–361
complete assessment for, 319
dependence on, psychology of, 345
dose and duration of, 320–322
efficacy of, 312–313
endogenous, in antinociceptive response system, 310
function of, 312–313
habitual patient files and, 359–360
in chronic pain, 312–323
in migraine headaches, 374–375
in multidisciplinary therapy, 319
in neuropathic pain, 314
in pediatric pain, 402
in sickle cell disease, 379–380
liability of physician and, 322
long-term use of, conditions for, 319
nurse-initiated protocols for, 461
oral, in corneal abrasions, 383
"pain-opioid downhill spiral," 317–318
patient demand for, physician and, 318–319
patient selection for, 320
patients at risk for problems with, 359
pharmacology of, 451–453
physiologic dependence on, 316–317
psychoactive properties of, 349–350
self-reinforcing properties of, 350–351
side effects of, 314
specific, 453–460
therapy with, goals of, 320
pain contracts for, 322
tolerance to, 315–316
use in austere environment, 588–590

Osmotic demyelination syndrome, 758

Osteoarthritis, 330

Osteopathy, 539–540

Osteopenia, in amenorrhea, 793

Outcomes research, in international emergency medicine, 237

Oxycodone, 459–460

Oxygen, in unstable/non-ST elevation myocardial infarction, 1030

P

Pacing, cardiac, electrocardiographic guidance for, 1192
indications for, 1191
in acute coronary syndromes, 1074

Pain, acute, pathophysiology of, **277–284**
and pain control, in emergency medicine, changing attitudes about, **297–306**
and perception of, 339
anxiety and, 340
assessment of, barriers to, 285–287
for pain management in prehospital environment, 419
beliefs and coping with, 341–342
chronic, 342
acute care physician and, 326–328
addiction in, 356–357
behavior in, 342–343
biological considerations in, 308
definition of, 307–308
drugs for, 324–325
evaluation of, 344–345
management of, in acute care setting, **307–338**
nonopioid therapy in, 323–324
opioids in, 312–323
prevalence of, 308
prevention of, 322
context of occurrence of, 339–340
expectations of, 341
focus of attention on, 340
intensity of, pain assessment instruments to rate, 287
learned, 340–341
memory of, 340
pathophysiology of, 530–532
pediatric. See *Pediatric pain.*
perspectives on, 286
psychological and social considerations in, 312
psychology of, **339–348**
sensations of, interpretation by brain, 281
temporal characteristics of, 290
treatment of, barriers to, bias as, 300
emergency department culture as, 302
emergency department environment as, 300–301
opioids as, 301–302
provider education as, 302–303
in emergency department, 523–524
undertreatment of, malpractice suit for, 582
visceral, 282

Pain and Policy Studies Group, of University of Wisconsin, 574–575, 579–580

Pain assessment instruments, for use in emergency department, **285–295**
numerical rating scale and, 288
picture scales as, 289
reliability and validity of, 287
to rate pain intensity, 287
verbal rating scales, 290
visual analog scale and, 288
visual analog scale versus numerical rating scale, 288

Pain clinics, multidisciplinary, 324

Pain guidelines, 522–523

Pain management, and research, in emergency department, 298–299
current state of, implications of, 520
federal and state barriers to, 575–576
initiatives to reduce, 576–579
in emergency medicine, education in, 468–469
future of, **467–475**
novel approaches to, 472–473
pain evaluation in, 469–470
studies of, 471–473
in prehospital environment, **415–431**
history of, 416
monitoring and assessment in, 425–426
myths concerning, 418
nonpharmacologic interventions in, 424–425
pain assessment for, 419
pain scales to assess, 420, 421
pharmacologic interventions in, 421–424
protocols for, 416–418
quality improvement in, 426–427
in wilderness and operational setting, **585–601**
inadequate, consequences of, 303–304
legal issues in, **573–584**
definitions associated with, 574–575
nonpharmacologic, use in austere environment, 597–598

Pain management system, assessment of pain in, 520–522
establishing of, **519–527**
managing of, 524

Pain pathways, chronic, 308–309

Pain receptors, and peripheral nerve fibers, 277–279

Pain Relief Act, 577

Pain signals, afferent, ascending pathways of, 280–281

Pain therapy, complementary and alternative, **529–549**
mind/body approaches to, 533–534

Painful dilemmas, **367–392**

Palliative care, complementary therapies in, 543–544

Pan Arab Society for Trauma and Emergency Medicine, 7–8

Pancreatic fistula, hyperchloremic anion gap acidoses in, 784

Paradehyde, elevated anion gap acidosis and, 775

Parecoxib, 449, 450

Patient attitudes, toward pain treatment, 299–300

Pediatric pain, assessment of, 396
multidimensional pain scales for, 398, 399
one-dimensional pain scales for, 397, 398
behavioral techniques in, 401
cognitive therapies in, 400
management of, as different from pain management in adults, 395–396
history of, 394–395
in emergency department, **393–414**
pharmacologic methods of, 401–402
nonpharmacologic interventions in, 400–401
physical interventions in, 401
procedural sedation in, 403–406
reduction of, for painful emergency procedures, 406–408

Pericardial effusions, causes of, 1188
ultrasound to detect, 1188–1190

Pharmacologic imaging, in acute coronary syndromes, 992–993

Pharmacology, basic, and advances in, in emergency medicine, **433–465**

Pheochromocytomas, 687–691
evaluation for, 689–690
localization of, 690
management of, 690–691
presentation in, 688

Phosphate, metabolism of, 713
abnormalities of, causes of, 715

Physical function, pain-related, 290–293

Physical interventions, in pain management, 401, 425

Physical therapy, in chronic pain, 323–324

Physician(s), acute care, chronic pain and, 326–328
emergency. See *Emergency physician(s)*.

Picture scales, to assess pain, 289

Polycystic ovarian syndrome, 823

Porphyria(s), **885–899**
acute intermittent, diagnosis of, 892
drugs inducing, 889, 890
enzyme deficiency in, 889
factors precipitating, 889–891
pathophysiology of, 889
signs and symptoms of, 891–892
treatment of, 892–893
classification of, 886
congenital erythropoietic, 896–897
delta-aminolevulinate dehydratase deficiency, 897–898
South African, 895–896

Porphyria cutania tarda, 885, 886–888
diagnosis of, 888
pathophysiology of, 886–888
signs and symptoms of, 888
treatment of, 888

Postpartum pituitary necrosis. See *Sheehan's syndrome*.

Potassium, body handling of, physiology of, 723–724
disorders of, **723–747**
excretion of, 725
intake of, 724
overload of, hyperkalemia in, 739–740
transcellular shifting of, 724

Potassium efflux blockers, and QT prolongation, 1203, 1205
toxicity of, 1205–1206

Pregnancy, thyrotoxicosis in, 676–677, 680

Prehospital care, development of emergency medicine and, 243

Prehospital care delivery systems, chain of resources for, 100, 101
development of, approach to, 100–101
formal systems for, 103
informal systems for, 101–103
systems approach for, 101
diversity around world, **99–114**
goal of, 100
level of service and equipment for, 104–105
providers in, training for, 107–109
service providers for, 105, 106

Project HOPE, and emergency services in Costa Rica, 37–38

Propofol, for pediatric sedation, 405
for procedural sedation and analgesia, 513–515

Propoxyphene, 313–314

Pseudoaddiction, 358–359

Pseudohyperkalemia, 736

Psychiatric disease, 343

Psychosis, in endocrine and metabolic disorders, 905–906

Public education, development of emergency medicine and, 243–244

Public health initiatives, international, injury prevention and, **85–98**

Pulmonary disease, chronic obstructive, steroids in, 822

Pulmonary edema, cardiogenic, assisted circulation in, 1118
disposition in, 1118–1119
emergency department evaluation in, 1108–1109
emergency department management in, 1109–1110
etiologies of, 1106–1108
modern management of, **1105–1125**
pathophysiology of, 1106
pharmacologic therapy in, 1110–1117
ventilatory support in, 1117–1118

Pulmonary embolism, 948–954
clinical presentation of, 949
D-dimer assays in, 950–952
diagnostic evaluation of, 949–953
elevation of cardiac biomarkers in, 970
risk factors for, 951
risk management strategies in, 953–954
ultrasound to evaluate, 1190–1191

Pulseless electrical activity, ultrasound to assess, 1190

Q

Quality of life, health-related, international emergency medicine and, 238

R

Red Cross, fundamental principles of, 122

Renal colic, 376–377

Renal failure, hyperkalemia in, 736–737

Renal insufficiency, hyperchloremic anion gap acidoses in, 782–783

Renal tubular acidoses, hyperchloremic anion gap acidoses in, 782–783

Renin-angiotensin-aldosterone system, 725

Reperfusion arrhythmias, in acute coronary syndromes, 1077–1078

Reperfusion therapy, acute, in acute myocardial infarction, **1043–1063**
indications and contraindications for, 1045–1046

Research, and pain management, in emergency department, 298–299
in international emergency medicine, current state of, 237–241
locus of, in international emergency medicine, 234–235
outcomes of, in international emergency medicine, 237

Research techniques, in high income countries, 232

Respiratory distress syndrome, acute, in diabetic ketoacidosis, 624

Respiratory illness, international emergency medicine and, 241

Rhabdomyolysis, in hyperosmolar hyperglycemic state, 645

Rheumatoid arthritis, 330

Rofecoxib, 450

Ropivacaine (Naropin), 485

S

Scalp lacerations, management of, in children, 408

Sedation, of children, 394, 403–406

Sedation and analgesia, adverse events in, patient factors and, 553–555
drug-dosing errors in, 556–557
procedural, adverse effects on
cardiovascular system, 557–559
adverse effects on dermatologic, allergic and neurologic systems, 565–566
adverse effects on gastrointestinal system, 564
adverse effects on pulmonary system, 559–564
adverse effects on renal and adrenal system, 564–565
adverse events in, epidemiology of, 551–553
medications for, 504–507
monitoring in, 507–509
new concepts in, **503–517**
pharmacology of, 511–515
preprocedural fasting for, 510–511
risks of, **551–572**

Seizures, in electrolyte disturbances, 866
in metabolic or endocrine disorders, 904–905

Sheehan's syndrome, 836–839
differential diagnosis of, 837–838
evaluation in, 838–839
management of, 839
pathophysiology of, 837
presentation in, 836–837

SIADH, causes of, 755, 756, 832
differential diagnosis of, 833–834
evaluation in, 834–835
management of, 835–836
pathophysiology of, 833
presentation in, 832–833

Sickle cell disease, 377–382
conventional therapy in, 378–381
fluid therapy in, 379
ketorolac in, 381
opiates in, 379–380
patient care in, 378

Sinus bradycardia, in acute coronary syndromes, 1069–1070

Sinus tachycardia, in acute coronary syndromes, 1066–1067

Society for Academic Emergency Medicine, 5–6

Sodium channel blockade, hyperkalemia in, 739

Sodium channel blockers, 1202, 1203
toxicity of, 1202–1205

Sodium-potassium-ATPase-blocker toxicity, 1206–1210

Somatoform pain disorders, 343–344

Sphere Project, 120–121

Spinal cord, anatomy of, 279

Starvation, 790–791

Steroids. See *Anabolic steroids.*

Stress testing, in acute coronary syndromes, 941–942, 990–993
in cocaine-associated chest pain, 1092

Stroke, acute ischemic, in severe hypertension, 1150–1151

Sudden death, congenital heart lesions in children and, 1238

Supraventricular tachyarrhythmias, in acute coronary syndromes, 1066–1069

Supraventricular tachycardia, in children, 1244
paroxysmal, in acute coronary syndromes, 1067–1068

Suturing of wounds, techniques for, in children, 407–408

Syndrome of inappropriate antidiuretic hormone secretion. See *SIADH.*

T

Tachyarrhythmias, supraventricular, in acute coronary syndromes, 1066–1069

Tachycardia(s), paroxysmal
supraventricular, in acute coronary syndromes, 1067–1068
supraventricular, in children, 1244
ventricular, in acute coronary syndromes, 1075–1076

Telecommunication technologies, for emergency medicine, 225–227

Testosterone, 816, 821

Thrombin inhibitors, in unstable/non-ST elevation myocardial infarction, 1038

Thromboembolism, in diabetic ketoacidosis, 624

Thrombolysis, prehospital, emergency cardiac care and, 1225–1228

Thyroid axis, in critical illness, evaluation of, 922–924
management of, 924
pathophysiology of, 922
presentation in, 922

Thyroid releasing hormone, in critical illness, 911–912

Thyroid stimulating hormone, thyroid testing and, 657–659

Thyroid storm, 677–678, 680–682

Thyroiditis, autoimmune, 652
silent, 671–672

Thyrotoxicosis, in newborn, 677
in pregnancy, 676–677, 680

Toxicology, cardiovascular challenges in, **1195–1217**

Training and education, in emergency medicine. See *Emergency medicine, training and education in.*

Tramadol, 313–314
in prehospital pain management, 423

Trauma response, development of emergency medicine and, 242–243

Triptans, in migraine headaches, 374

Troponins, cardiac, 941, 963–964, 970, 1091

U

Ultrasound, and echocardiography, in emergency department, **1179–1194**
B mode, 1182
Doppler, 1182–1183
M mode, 1182
of heart, apical view, 1186–1187, 1188
equipment for, 1183–1184
parasternal long view, 1185, 1187
parasternal short view, 1185, 1187
scanning techniques in, 1184
subcostal view, 1184–1185, 1186
physics of, 1181–1182
to assess pulseless electrical activity, 1190
to detect pericardial effusions, 1188–1190
to estimate central venous pressure, 1191
to evaluate pulmonary embolism, 1190–1191

United Nations, emergency medicine and, 46–47, 50

United Nations Children's Fund, 46–47

United Nations organizations, 122

United States Agency for International Development, 96

United States Medical Licensing Exam (USMLE), 201

V

Variegate porphyria, 895–896

Ventilatory support, in cardiogenic pulmonary edema, 1117

Ventricular arrhythmias, in acute coronary syndromes, 1074–1077

Ventricular contractions, premature, in acute coronary syndromes, 1074–1075

Ventricular fibrillation, in acute coronary syndromes, 1077

Ventricular hypertrophy, left, in acute coronary syndromes, 1015–1021, 1022–1023, 1024

Ventricular paced rhythm, right, in acute coronary syndromes, 1010–1015

Ventricular tachycardia(s), in acute coronary syndromes, 1075–1076

Video, compressed and uncompressed, for emergency medicine, 221–223
live, for emergency medicine, 221

Visceral pain, 282

Visual analog scale, pain assessment instruments and, 288

Voluntary organizations, private, for funding of relief and development, 123

W

Warfare and diaster. See *Conflict, modern.*

Water imbalance, disorders of, **749–770**
effects on brain cells, 750, 751

Weakness, generalized, in electrolyte or metabolic abnormalities, 903

Wenckebach atrioventricular blocks, in acute coronary syndromes, 1071

Wernicke-Korsakoff syndrome, 796

WHO/United Nations Children's Expeditionary Fund, conference on primaryhealth care, 151–152

Wilderness, pain management in, **585–601**

Wolff-Parkinson-White syndrome, in children, 1244–1245

World Association for Disaster and Emergency Medicine, 6

World Bank, 47, 52
Minimum Package of Health Services of, 15

World Bank Group, 95

World Health Day - 2004, 95

World Health Organization (WHO), 46, 53, 94–95
Department of Injuries and Violence Prevention, 94
emergency medicine and, 233
prehospital injury care guidelines and, 95
world health report of, 14, 77–78